Search
Epicept NP-1
go.drugbank.com/drugs/DB05492InvestigationalPeripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.
Furosemide
go.drugbank.com/drugs/DB00695ApprovedInvestigationalVet approved[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body.
19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicit19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. … After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalIt is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
Eugenol
go.drugbank.com/drugs/DB09086ApprovedInvestigationalEugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves.
Dexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approved[A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions. … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately
Gadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigational[A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnIt is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Cholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigational[PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019.